Wells Fargo & Company Puma Biotechnology, Inc. Transaction History
Wells Fargo & Company
- $468 Billion
- Q2 2025
A detailed history of Wells Fargo & Company transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 28,026 shares of PBYI stock, worth $136,486. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,026
Previous 23,448
19.52%
Holding current value
$136,486
Previous $69,000
39.13%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding PBYI
# of Institutions
124Shares Held
33.3MCall Options Held
68.2KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.1 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$18.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.4 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$9.78 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.87MShares$9.13 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $222M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...